靶向辅助化疗：一个有待证实的好想法！ - Suppr

Suppr

超能文献

Targeting adjuvant chemotherapy: a good idea that needs to be proven!

作者信息

Hayes Daniel F

机构信息

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

出版信息

J Clin Oncol. 2012 Apr 20;30(12):1264-7. doi: 10.1200/JCO.2011.38.4529. Epub 2012 Feb 21.

DOI:10.1200/JCO.2011.38.4529

PMID:22355050

Abstract

摘要

相似文献

Targeting adjuvant chemotherapy: a good idea that needs to be proven!靶向辅助化疗：一个有待证实的好想法！

J Clin Oncol. 2012 Apr 20;30(12):1264-7. doi: 10.1200/JCO.2011.38.4529. Epub 2012 Feb 21.

Is adjuvant chemotherapy useful for women with luminal a breast cancer?辅助化疗对激素受体阳性A型乳腺癌女性患者有用吗？

J Clin Oncol. 2012 Apr 20;30(12):1260-3. doi: 10.1200/JCO.2011.37.7879. Epub 2012 Feb 21.

Patients with anti-HER2 responsive disease: definition and adjuvant therapies.抗 HER2 反应性疾病患者：定义和辅助治疗。

Breast. 2011 Oct;20 Suppl 3:S132-4. doi: 10.1016/S0960-9776(11)70310-1.

To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?换用还是不换用：他莫昔芬与雷洛昔芬（STAR）试验的研究是否应改变我们的决策？

Taiwan J Obstet Gynecol. 2008 Sep;47(3):372-4. doi: 10.1016/S1028-4559(08)60149-7.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.曲妥珠单抗辅助治疗局部晚期或炎性乳腺癌的 NeOAdjuvant Herceptin（NOAH）研究中，接受新辅助治疗后行手术治疗的 HER2 阳性患者。

Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.

The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.芳香化酶抑制剂在激素受体阳性绝经后乳腺癌女性中的应用。

J Clin Oncol. 2005 Sep 20;23(27):6807-9. doi: 10.1200/JCO.2005.02.3952.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?早期乳腺癌中无化疗的抗 HER2 治疗是否可行？

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2.

[DCIS and HER2/neu].[导管原位癌与人类表皮生长因子受体2/神经（HER2/neu）]

Onkologie. 2002 Dec;25 Suppl 5:11-2; discussion 13.

Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.

Clin Breast Cancer. 2006 Apr;7(1):51-8. doi: 10.3816/CBC.2006.n.013.

The continued evidence from overviews: what is the clinical utility?系统评价的持续证据：临床实用性如何？

Breast. 2013 Aug;22 Suppl 2:S8-11. doi: 10.1016/j.breast.2013.07.002.

引用本文的文献

Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.新辅助内分泌治疗与新辅助化疗后病理完全缓解的生存结局：一项全国性回顾性数据库研究。

Breast Cancer Res Treat. 2025 Jul;212(1):161-172. doi: 10.1007/s10549-025-07717-3. Epub 2025 May 11.

Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy-An Observational Study.树突状细胞亚群与新辅助化疗后乳腺癌的预后特征相关：一项观察性研究。

Int J Mol Sci. 2023 Oct 31;24(21):15817. doi: 10.3390/ijms242115817.

Cost-utility analysis of genomic profiling in early breast cancer in Colombia.哥伦比亚早期乳腺癌基因图谱分析的成本效益分析

Cost Eff Resour Alloc. 2023 Jul 10;21(1):42. doi: 10.1186/s12962-023-00449-5.

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response.为达到病理完全缓解的乳腺癌患者量身定制新辅助化疗。

Transl Cancer Res. 2020 Feb;9(2):1205-1214. doi: 10.21037/tcr.2020.01.01.

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.新辅助化疗或内分泌治疗用于激素受体高度阳性且人表皮生长因子受体2阴性的乳腺浸润性导管癌

JAMA Netw Open. 2021 Mar 1;4(3):e211785. doi: 10.1001/jamanetworkopen.2021.1785.

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.乳腺癌中 Ki67 的评估：国际乳腺癌 Ki67 工作组的最新建议。

J Natl Cancer Inst. 2021 Jul 1;113(7):808-819. doi: 10.1093/jnci/djaa201.

A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.基于信息价值的乳腺癌管理 21 基因检测研究分析。

Value Health. 2019 Oct;22(10):1102-1110. doi: 10.1016/j.jval.2019.05.004. Epub 2019 Aug 7.

Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.早期激素受体阳性乳腺癌的基因表达检测：了解差异

JNCI Cancer Spectr. 2017 Dec 11;1(1):pkx008. doi: 10.1093/jncics/pkx008. eCollection 2017 Sep.

Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.多基因表达谱分析检测指导浸润性早期乳腺癌女性辅助治疗决策的成本效果分析。

Pharmacogenomics J. 2020 Feb;20(1):27-46. doi: 10.1038/s41397-019-0089-x. Epub 2019 May 27.

Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.年龄对新辅助化疗后局部晚期乳腺癌病理完全缓解和局部区域复发的影响。

Biomed J. 2019 Feb;42(1):66-74. doi: 10.1016/j.bj.2018.10.007. Epub 2019 Mar 28.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验